Article, 2024

Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20-treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder

MULTIPLE SCLEROSIS AND RELATED DISORDERS, ISSN 2211-0348, Volume 85, 10.1016/j.msard.2024.105523

Contributors

Stastna, D. 0000-0003-2418-4847 (Corresponding author) [1] [2] Vachova, M. [1] [2] [3] Dusek, P. 0000-0003-4307-8206 [1] [2] Fistravec, G. [4] Drahota, J. 0000-0003-3416-2094 [1] [2] [4] Menkyova, I. [1] [2] [5] [6] Varju, E. [7] [8] Horakova, Dana [1] [2] Havrdova, Eva 0000-0002-9543-4359 [1] [2] Nytrova, P. [1] [2]

Affiliations

  1. [1] Charles Univ Prague, Ctr Clin Neurosci, Fac Med 1, Katerinska 30, Prague 12000, Czech Republic
    2. [NORA names: Czechia; Europe, EU; OECD];
  2. [2] Charles Univ Prague, Ctr Clin Neurosci, Fac Med 1, Katerinska 30, Prague 12000, Czech Republic
    3. [NORA names: Czechia; Europe, EU; OECD];
  3. [3] Hosp Teplice, KZ a s, Dept Neurol, Teplice, Czech Republic
    4. [NORA names: Czechia; Europe, EU; OECD];
  4. [4] Endowment Fund IMPULS, Prague, Czech Republic
    5. [NORA names: Czechia; Europe, EU; OECD];
  5. [5] Slovak Med Univ, Fac Med, Dept Neurol, Bratislava, Slovakia
    6. [NORA names: Slovakia; Europe, EU; OECD];

Abstract

Abstract not displayed. As this article is not marked as Open Access, it is unclear if we are allowed to show the abstract. Please use the link in the sidebar to view the data provider version of the article including abstract.

Keywords

COVID-19, Evusheld, Multiple sclerosis, Neuromyelitis optica spectrum disorder, Tixagevimab/cilgavimab

Data Provider: Clarivate

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+